AQR Capital Management’s UroGen Pharma URGN Stock Holding History

AQR Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.49M	Buy	149,228 +5,168	+4%	+$140K	﹤0.01%	1936
2026 Q1	$2.59M	Sell	144,060 -9,353	-6%	-$188K	﹤0.01%	2178
2025 Q4	$3.59M	Sell	153,413 -50,778	-25%	-$1.1M	﹤0.01%	1776
2025 Q3	$4.07M	Sell	204,191 -27,383	-12%	-$492K	﹤0.01%	1573
2025 Q2	$3.17M	Buy	231,574 +117,508	+103%	+$1.13M	﹤0.01%	1519
2025 Q1	$1.26M	Buy	114,066 +88,577	+348%	+$944K	﹤0.01%	1877
2024 Q4	$271K	Sell	25,489 -92,450	-78%	-$1.11M	﹤0.01%	2537
2024 Q3	$1.5M	Buy	117,939 +87,649	+289%	+$1.3M	﹤0.01%	1637
2024 Q2	$508K	Sell	30,290 -11,972	-28%	-$170K	﹤0.01%	2049
2024 Q1	$634K	Buy	42,262 +23,879	+130%	+$390K	﹤0.01%	1865
2023 Q4	$276K	Buy	+18,383	New	+$239K	﹤0.01%	2092

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

AQR Capital Management's URGN Position: Q2 2026 in Review

AQR Capital Management increased its UroGen Pharma (URGN) stake by 3.6% in Q2 2026, buying an estimated $140K and bringing the position to 149,228 shares worth $5.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1936.

AQR Capital Management first reported a position in URGN in Q4 2023 and has held it in 11 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

AQR Capital Management held 149,228 shares of UroGen Pharma worth $5.49M as of Q2 2026.
AQR Capital Management bought 5,168 UroGen Pharma shares in Q2 2026, an estimated $140K.
UroGen Pharma made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1936 holding.
AQR Capital Management first reported a position in UroGen Pharma in Q4 2023 and has held it in 11 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.